Korea National Institute of Health Launches Biobank for “Cadaveric Normal Tissues”

3,648 Human Biospecimens Secured Over 10 Years

Establishing a Foundation for Comparative Studies with Diseased Tissues

A national-scale biobank project will be launched in earnest to more precisely identify the causes and progression of diseases by collecting healthy organ tissues, such as the heart, from deceased donors and comparing and analyzing them with diseased tissues.


Accelerating Precision Medicine with the "Innovative Biobank" View original image

On August 14, the National Institute of Health under the Korea Disease Control and Prevention Agency announced that it will newly include the field of normal tissues derived from deceased donors in its "Innovative Biobank Consortium Support Project" to strengthen the foundation for precision medicine research.


Until now, the biobank project has collected human resources such as blood, tissue, and DNA from patients with chronic cerebrovascular diseases, sarcoma cancers, and hereditary developmental disorders, utilizing related information for research. However, there have been limitations in securing healthy organ tissues, as accurate characterization of diseased tissues requires comparison with normal tissues from the same organ.


In response, starting this year, the National Institute of Health will expand the scope of collection to include healthy organ tissues such as the heart, obtained from deceased donors. The normal tissues and related information acquired through the newly launched "Consortium for Normal Tissues Derived from Cadavers" (project led by Professor Oh Ji-Won of the Yonsei University-Industry Foundation) will be used as reference data for comparison with diseased tissues. Through this, the causes and progression of diseases may be identified, and precision medicine research tailored to individual genetic characteristics is also expected to benefit.


The Innovative Biobank Project began with chronic cerebrovascular diseases in 2016 and has since expanded its scope to include sarcoma cancers in 2021, and gynecologic cancers and hereditary developmental disorders in 2024. This year, with the conclusion of the gynecologic cancer consortium and new support for the cadaver-derived normal tissue consortium, the national research infrastructure is being established to link both prerelease and post-mortem human resources.


Currently, the Innovative Biobank Consortium is operated across four fields: chronic cerebrovascular diseases, sarcoma cancers, hereditary developmental disorders, and normal tissues derived from cadavers.


As of the end of last year, the project had built up a total of 3,648 samples of high-quality human-derived materials(DNA, plasma, serum, PBMC, tissue, etc.). Of these, 1,645 samples were distributed to domestic researchers and used for precision medicine research. These efforts have resulted in 46 SCI-level papers, 10 patents, three cases of technology transfer, and one case of commercialization to date.


In particular, there were five international journal papers per 1 billion won of research funding, marking research productivity 3.1 times higher than the national R&D project average of 1.6 papers. The average impact factor (IF) of these papers was 6.5, 5.8 times higher than the national R&D average of 1.12. There have also been real cases of successful technology transfer, such as digital therapeutics for dementia, self-care mental health management technologies, and AI-based content toxicity analysis technologies. Among these, the digital therapeutic for dementia has been successfully commercialized.


Meanwhile, according to the "National Human Bio-Resource Bank Annual Report," in 2025 alone, an additional 110,000 population-based and 50,000 disease-based human samples will be secured, increasing the cumulative total to 1.39 million samples. By the end of 2025, the cumulative number of human sample distributions to domestic research institutes and companies stood at 5,854 cases, while related patents reached 246.


Jeon Jae-Pil, Director of the Future Medicine Research Division at the National Institute of Health, stated, "The Innovative Biobank Consortium is a national research project that promotes the practical application of precision medicine based on high-quality human resources and in-depth data," adding, "We will continue to support precision medicine research for rare and intractable diseases, where the public can truly feel the benefits."



This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing